

ENTERO HEALTHCARE SOLUTIONS LIMITED

CODE FOR PROHIBITION OF INSIDER TRADING, A CODE OF PRACTICES AND PROCEDURES FOR FAIR DISCLOSURE OF UNPUBLISHED PRICE SENSITIVE INFORMATION AND CODE OF CONDUCT TO REGULATE, MONITOR AND REPORT TRADING BY INSIDERS, CONTAINING THE REQUISITE INFORMATION AS REQUIRED UNDER THE INSIDER TRADING REGULATIONS

Approving Authority:	Board of Directors of the Company
Original Issue Date:	25 th August 2023
Version No.:	1.0
Review Cycle:	At such periods as the Board of Directors may deem fit.
Applicability	Applicable to the Company and its subsidiaries



ENTERO HEALTHCARE SOLUTIONS LIMITED

CODE OF FAIR DISCLOSURE OF UNPUBLISHED PRICE SENSITIVE INFORMATION

Code of Conduct for Prevention and for regulation, monitoring and reporting of Insider Trading for "designated employees" and Code of Practices for fair disclosure of Unpublished Price Sensitive Information.

1. INTRODUCTION

- 1.1 The Securities and Exchange Board of India (SEBI) has formulated the SEBI (Prohibition of Insider Trading) Regulations, 2015 ['PIT Regulations'].
- 1.2 Insider trading means 'trading in 'Securities' of a Company by its Directors, Employees or other 'Insiders' based on 'Unpublished Price Sensitive Information'. Such activities by Insiders erode the investors' confidence in the integrity of the management and are unhealthy for the capital markets. The PIT Regulations prohibits an insider of a Company to deal in the securities of such Company while in possession of any unpublished price sensitive information. The PIT Regulations also prohibits an insider to 'communicate, counsel or procure', whether 'directly or indirectly', any unpublished price sensitive information to any person including insiders, who while in possession of such information may 'deal' in the securities of the Company listed or proposed to be listed. Every Director, Officer, Designated Employee of the Company has a duty to safeguard the confidentiality of all the information obtained during the course of his /her employment at the Company.

2. DEFINITIONS

- 2.1 "Act" means the Securities and Exchange Board of India Act, 1992.
- 2.2 **"Board**" means the Board of Directors of the Company.
- 2.3 **"Code" or "Code of Conduct"** shall mean the "Code of Conduct for prevention of insider trading for designated employees" and Code of Practices for fair disclosure of unpublished price sensitive information by insiders of Entero Healthcare Solutions Limited.
- 2.4 **"Company"** means Entero Healthcare Solutions Limited.

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com



- 2.5 **"Compliance Officer"** means any senior officer. designated so and reporting to the Board of Directors, who is financially literate and is capable of appreciating requirements for legal and regulatory compliance under these regulations and who shall be responsible for compliance of policies, procedures, maintenance of records, monitoring adherence to the rules for the preservation of unpublished price sensitive information, monitoring of trades and the implementation of the codes specified in these regulations under the overall supervision of the Board of Directors of the listed Company.
- 2.6 "Connected Person" means Any person who is or has during the six months prior to the concerned act been associated with a company, directly or indirectly, in any capacity including by reason of frequent communication with its officers or by being in any contractual, fiduciary or employment relationship or by being a director, officer or an employee of the Company or holds any position including a professional or business relationship between himself and the company whether temporary or permanent, that allows such person, directly or indirectly, access to unpublished price sensitive information or is reasonably expected to allow such access.
- 2.7 Without prejudice to the generality of the foregoing, the persons falling within the following categories shall be deemed to be connected persons unless the contrary is established:
 - a. An immediate relative of connected persons specified in clause (i); or
 - b. A holding company or associate company or subsidiary company; or
 - c. An intermediary as specified in Section 12 of the Securities and Exchange Board of India Act, 1992 or an employee or director thereof; or
 - d. An investment company, trustee company, asset management company or an employee or director thereof; or
 - e. An official of a stock exchange or of clearing house or corporation; or
 - f. A member of board of trustees of a mutual fund or a member of the board of directors of the asset management company of a mutual fund or is an employee thereof; or
 - g. A member of the Board of directors or an employee, of a public financial institution as defined in section 2 (72) of the Companies Act, 2013; or
 - h. An official or an employee of a self-regulatory organization recognised or authorized by the Board; or

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com



- i. A banker of the Company; or
- j. A concern, firm, trust, Hindu undivided family, company or association of persons wherein a director of the Company or his immediate relative or banker of the Company, has more than ten per cent, of the holding or interest.
- 2.8 "Director" means a member of the Board or Directors of the company.
- 2.9 **"Generally available information"** means information that is accessible to the public on a non- discriminatory basis including information published on website of the Stock Exchange(s).
- 2.10 "Immediate Relative" means a spouse of a person, and include parent. sibling, and child of such person or of the spouse, any of whom is either dependent financially on such person, or consults such person in taking decisions relating to trading in securities.
- 2.11 "Insider" means any person who is
 - a. connected person; or
 - b. In possession of or having access to unpublished price sensitive information;
- 2.12 "Promoter" means and includes:
 - a. The person or persons who are in control of the issuer;
 - b. The person or persons who are instrumental in the formulation of a plan or programme pursuant to which specified securities are offered to public;
 - c. The person or persons named in the offer document as promoters: Provided that a director or officer of the issuer or a person, if acting as such merely in his professional capacity, shall not be deemed as a promoter;
 - d. **"Promoter" and "Promoter Group"** shall have the meaning assigned to it under the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 or any modification thereof;

Provided further that a financial institution, scheduled bank, foreign institutional investor and mutual fund shall not be deemed to be a promoter merely by virtue of the fact that ten per cent or more of the equity share capital of the issuer is held by such person; Provided further that such financial institution, scheduled bank and foreign institutional investor shall be treated as promoter for the subsidiaries or companies promoted by them or for the mutual

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com



fund sponsored by them.

- 2.13 "**Regulations**" or **"these Regulations**" or **"PIT Regulations"** means SEBI (Prohibition of Insider Trading), Regulations, 2015 as amended from time to time.
- 2.14 "**Securities**" includes Share. scrips, stock, bonds, debentures, debenture stock or other marketable securities of a like nature in or of any incorporated company or other body corporate; b. Derivatives; c. Rights or interest in securities;
- 2.15 **"Unpublished Price Sensitive Information" or "UPSI"** means any information, relating to a company or its securities, directly or indirectly, that is not generally available which upon becoming generally available, is likely to materially affect the price of the securities and shall, ordinarily including but not restricted to, information relating to the following:
 - a. financial results;
 - b. dividends;
 - c. change in capital structure;
 - d. mergers, de-mergers, acquisitions, de-listings, disposals and expansion of business and such other transactions;
 - e. changes in key managerial personnel; and
 - f. material events in accordance with the SEBI (Listing Obligations & Disclosure Requirements) Regulation 2015.
- 2.16 **"Takeover Regulations"** means the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and any amendments thereto.
- 2.17 **"Trading"** means and includes subscribing, buying, selling, dealing, pledging or agreeing to subscribe, buy, sell, deal in any securities, and "trade" shall be construed accordingly.
- 2.18 "**Trading day**" mean a day on which the recognized stock exchanges are open for trading;
- 2.19 **"Designated Person"** shall include the following persons:

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com



- a. Every Promoter and promoter group and all Directors whether executive, non-executive or independent;
- b. CEO and employees upto two levels below CEO of Listed Company, intermediary or fiduciary and its material subsidiaries irrespective of their functional role and ability to have access to UPSI;
- c. Employees in the category of Key Managerial Personnel, SBU heads, Entity partners and CXOs;
- d. The assistant and secretaries of point (b) above and direct reportees that reportees of above clause b who are under the designation of GM, AGM or Senior Manager;
- e. Permanent invitees/invitees to the Board meeting and committee meetings;
- f. Personal assistant/secretary to all the above persons;
- g. All other employees of the Company and its material subsidiaries and associate companies, including all employees in legal/secretarial and finance at corporate office and Reginal Finance leads, Business Development, treasury, taxation departments,, compliance departments, internal audit department, business/investor relations and corporate communication department. and chief executive officer / managing director's office and chairman's office;
- h. Persons employed on contract basis and performing similar roles or having similar responsibilities as persons mentioned in (b), (c) and (d) above;
- i. And such other persons as may be notified by the Compliance Officer as per direction of the Board considering the objectives of the Code
- j. Immediate Relatives of all the above persons
- k. All other person as may be notified by the Compliance officer.

All terms used in this Code but not defined hereinabove shall have the meanings prescribed to them under but defined in the Securities and Exchange Board of India Act, 1992, the Securities Contracts (Regulation) Act,1956, the Depositories Act,1996 or the Companies Act, 2013 and rules and regulations made there under.

2.20 **"Key Managerial Personnel"** means person as defined in Section 2(51) of the Companies Act, 2013.

2.21 **"Legitimate purpose"** shall mean sharing of UPSI by an Insider in a manner that meets the following criteria:

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com



- The sharing is strictly on a need-to-know basis;
- The sharing is in the interest of the Company;
- The sharing is with only one or more of the following persons, viz. Promoters, business associates, partners, collaborators, lenders, customers, suppliers, merchant bankers, legal advisors, auditors, insolvency professionals or other advisors or consultants; and
- The sharing has not been carried out to evade or circumvent the prohibitions laid down under the SEBI (PIT) Regulations.

The Policy for determination of "Legitimate Purpose" for sharing Unpublished Price Sensitive Information is appended as "Annexure 2" to this Code.

2.22 **"Whistle Blower**" means an employee who reports instance of leak of price sensitive information under this Policy.

3. APPLICABILITY

3.1 This Code shall be applicable to Promoters including member(s) of Promoter group, all the Directors, Designated Persons, and Concerned Advisers/Consultants/Retainers of the Company and Connected Persons as defined herein above.

4. DUTIES OF COMPLIANCE OFFICER

- 4.1 The Compliance Officer shall report on insider trading to the Board of Directors of the Company and in particular, shall provide reports to the Chairperson of the Audit Committee, or to the Chairperson of the Board of Directors at such frequency as may be stipulated by the Board of Directors.
- 4.2 Prescribing procedures for various activities referred to in the Code.
- 4.3 Monitoring adherence to the regulations for the preservation of UPSI, Grant of pre-clearance approvals to the Designated Persons for dealings in the Company's Securities by them / their Dependents and monitoring of such dealings.
- 4.4 Maintaining confidentially a list of securities as a "restricted list" which shall be used as a base for approving or rejecting applications for preclearance of trades.

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com

Corporate office : Unit No. 605 & 606, 6th Floor, Trade Centre, Bandra Kurla Complex, Bandra (East), Mumbai – 400051. Tel.: 022-26529100 / 69019100, CIN: U74999HR2018PLC072204



- 4.5 Maintenance of a record of prohibited periods specified from time to time.
- 4.6 The Compliance Officer shall assist all the Employees in addressing any clarifications regarding the Regulations and this Code.
- 4.7 Determination of trading window closure and re-opening periods.
- 4.8 Seeking declarations from the applicant towards possession of UPSI and its accuracy.
- 4.9 The compliance officer shall approve and publicly disclose the trading plan presented to him/her by the insider after which trades may be carried out on behalf of the insider in accordance with such plan.
- 4.10 The compliance officer shall review the trading plan to assess whether the plan would have any potential for violation of the regulations and shall be entitled to seek such express undertakings as may be necessary to enable such assessment and to approve and monitor the implementation of the plan.
- 4.11 In case any UPSI is in possession of an insider at the time of formulation of trading plan, the compliance officer shall confirm that unless such unpublished price sensitive information becomes generally available, the commencement of any trading plan shall be deferred.
- 4.12 The compliance officer shall notify the trading plan to the stock exchanges on which the securities of the Company are listed.
- 4.13 The Compliance officer shall maintain records of all the declarations in the appropriate form given by the directors/ officers / designated employees for a minimum period of five years.
- 4.14 Compliance of policies, procedures, maintenance of records, preservation of unpublished price sensitive information, monitoring of trades and the implementation of the codes specified in the regulations under the overall supervision of the board of directors of the listed company.
- 4.15 Ensuring that information shared with Analysts and Research Personnel is not UPSI.

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com

Corporate office : Unit No. 605 & 606, 6th Floor, Trade Centre, Bandra Kurla Complex, Bandra (East), Mumbai – 400051. Tel.: 022-26529100 / 69019100, CIN: U74999HR2018PLC072204



- 4.16 Ensure that appropriate and fair response is given to queries on news reports and requests for verification or market rumours' by regulatory authorities.
- 4.17 Developing best practices to make transcripts or records of proceedings of meetings with analysts and other investor relations conferences on the official website to ensure official confirmation and documentation of disclosures made.
- 4.18 Where there is a violation of regulations, the compliance officer or the company shall immediately inform SEBI about such violation.

5. PRESERVATION OF "PRICE SENSITIVE INFORMATION"

- 5.1 All information shall be handled within the Company on a need-to-know basis and no unpublished price sensitive information shall be communicated to any person except in furtherance of the insider's legitimate purposes, performance of duties or discharge of his legal and other official duties and obligations.
- 5.2 Unpublished price sensitive information may be communicated, provided, allowed access to or procured, in connection with a transaction which entails:
 - a) an obligation to make an open offer under the takeover regulations where the Board of Directors of the Company is of informed opinion that the proposed transaction is in the best interests of the Company; or
 - b) not attracting the obligation to make an open offer under the takeover regulations but where the Board of Directors of the Company is of informed opinion that the proposed transaction is in the best interests of the Company and the information that constitute unpublished price sensitive information is disseminated to be made generally available at least two trading days prior to the proposed transaction being effected in such form as the Board of Directors may determine.
- 5.3 However, the Board of Directors shall require the parties to execute agreements to contract confidentiality and non-disclosure obligations on the part of such parties and such parties shall keep information so received confidential, except for the limited purpose and shall not otherwise trade in securities of the Company when in possession of unpublished price sensitive information Need to Know:
 - a) "Need to Know" basis means that UPSI should be disclosed only to those within the Company who need the information to discharge

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com

Corporate office : Unit No. 605 & 606, 6th Floor, Trade Centre, Bandra Kurla Complex, Bandra (East), Mumbai – 400051. Tel.: 022-26529100 / 69019100, CIN: U74999HR2018PLC072204



their duty and whose possession of such information will not give rise to a conflict of interest or appearance of misuse of the information.

b) All non-public price sensitive information directly received by any employee should immediately be reported to the head of the department.

6. TRADING PLAN

- 6.1 An insider shall be entitled to formulate a trading plan for dealing in securities of the Company and present it to the Compliance Officer for approval and public disclosure pursuant to which trades may be carried out on his behalf in accordance with such plan.
- 6.2 Trading Plan shall;
 - a) not entail commencement of trading on behalf of the insider earlier than six months from the public disclosure of the plan;
 - b) not entail trading for the period between the twentieth trading day prior to the last day of any financial period for which results are required to be announced by the issuer of the securities and the second trading day after the disclosure of such financial results;
 - c) entail trading for a period of not less than twelve months;
 - c) not entail overlap of any period for which another trading plan is already in existence;
 - d) set out either the value of trades to be effected or the number of securities to be traded along with the nature of the trade and the intervals at, or dates on which such trades shall be effected; and
 - e) not entail trading in securities for market abuse.
- 6.3 The Compliance Officer shall review the trading plan to assess whether the plan would have any potential for violation of these regulations and shall be entitled to seek such express undertakings as may be necessary to enable such assessment and to approve and monitor the implementation of the plan.
- 6.4 The Trading Plan once approved shall be irrevocable and the Insider shall mandatorily have to implement the plan, without being entitled to either deviate from it or to execute any trade in the securities outside the scope of the trading plan.

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com

Corporate office : Unit No. 605 & 606, 6th Floor, Trade Centre, Bandra Kurla Complex, Bandra (East), Mumbai – 400051. Tel.: 022-26529100 / 69019100, CIN: U74999HR2018PLC072204



- 6.5 However, the implementation of the trading plan shall not be commenced, if at the time of formulation of the plan, the Insider is in possession of any unpublished price sensitive information and the said information has not become generally available at the time of the commencement of implementation. The commencement of the Plan shall be deferred until such unpublished price sensitive information becomes generally available information. Further, the Insider shall also not be allowed to deal in securities of the Company, if the date of trading in securities of the Company, as per the approved Trading Plan, coincides with the date of closure of Trading Window announced by the Compliance Officer.
- 6.6 Upon approval of the trading plan, the compliance officer shall notify the plan to the stock exchanges on which the securities are listed.

7. TRADING PLAN AND TRADING CLOSURE

- 7.1 The Trading Window shall be closed ordinarily but not restricted to, when information relating UPSI is made generally available by the Company. The Trading Window shall be opened 48 (Forty-eight) hours after the UPSI is made generally available by the Company.
- 7.2 The Trading Window shall be, inter-alia closed at the time of:

Details of	Period of Closure of Window						
Unpublished Information	Commencing From	Ending On					
Declaration	first day of the month immediately following the end of quarter/ Half Year/ Annual)	48 hours after the information has been Generally Available by the Company					
Declaration of Dividends (interim and final)	7 days before the Board Meeting	48 hours after the information has been					

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com



		Generally Available by the Company
Change in capital structure	Date of Issue of Notice/ Agenda of the Board Meeting or intimation Stock Exchange whichever is earlier	48 hours after the information has been Generally Available by the Company
Mergers, De- mergers, acquisitions, delisting's, disposals and expansion of business and such other transactions	Date of Issue of Notice/ Agenda of the Board Meeting or intimation Stock Exchange whichever is earlier	48 hours after the information has been Generally Available by the Company
Changes in Key Managerial Personnel	Date of Issue of Notice/ Agenda of the Board Meeting or intimation Stock Exchange whichever is earlier	48 hours after the information has been Generally Available by the Company
Material events in accordance with the listing agreement	Date of Issue of Notice/ Agenda of the Board Meeting or intimation Stock Exchange whichever is earlier	48 hours after the information has been Generally Available by the Company

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com



Issue of Securities by way of public/rights/ bonus etc.;	Date of Issue of Notice/ Agenda of the Board Meeting or intimation Stock Exchange whichever is earlier	48 hours after the information has been Generally Available by the Company
Disposal of whole or substantially whole of the undertaking	Date of signing of definitive agreement Issue of Notice/ Agenda of the Board Meeting or intimation Stock Exchange whichever is earlier	48 hours after the information has been Generally Available by the Company
Any significant changes in policies, plans or operations of the Company	Date of Issue of Notice/ Agenda of the Board Meeting or intimation Stock Exchange whichever is earlier	48 hours after the information has been Generally Available by the Company

- 7.3 The trading period, i.e., the trading period of the stock exchanges, called "trading window" is available for trading in the company's securities.
- 7.4 When the trading window is closed, the Designated Persons and whistle blower as defined in the Code shall not in the company's securities in such period.
- 7.5 The Trading Window shall also be applicable to any person having contractual or fiduciary relation with the Company, such as Auditors, Accountancy Firms, Law Firms, Analysts, Consultants etc., Assisting or Advising the Company.
- 7.6 All Designated Persons shall conduct all their dealings in the securities of the Company only in a valid trading window and shall not deal in any

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com



transaction involving the purchase or sale of the Company's securities during the periods when the trading window is closed, as referred to in Point No. (7.2) above or during any other period as may be specified by the Company from time to time.

- 7.7 Unless otherwise specified by the Compliance Officer, the Trading Window for Dealing in Securities of the Company shall be closed for the following purposes
 - a. Declaration of financial results (quarterly, and annual) stand alone and consolidated;
 - b. Declaration of dividends (interim and final);
 - c. Issue of Securities by way of public/rights/bonus etc.;
 - d. Any major expansion plans or execution of new projects;
 - e. Amalgamation, mergers, de-mergers takeovers and buy-back;
 - f. Changes in key managerial personnel;
 - g. Material events in accordance with the listing agreement;
 - h. Changes in Capital Structure;
 - i. Disposal of whole or substantially whole of the undertaking, and
 - j. Any significant changes in policies, plans or operations of the Company.
- 7.8 The Compliance Officer shall intimate the closure of trading window to all the designated employees of the Company when he determines that a designated person or class of designated persons can reasonably be expected to have possession of unpublished price sensitive information. Such closure shall be imposed in relation to such securities to which such unpublished price sensitive information relates.
- 7.9 The Compliance Officer after taking into account various factors including the unpublished price sensitive information in question becoming generally available and being capable of assimilation by the market, shall decide the timing for re-opening of the trading window, however, in any event it shall not be earlier than 48 hours after the information becomes generally available.
- 7.10 The trading window shall also be applicable to any person having contractual or fiduciary relation with the Company, such as auditors, accountancy firms, law firms, analysts, consultants etc., assisting or advising the Company.



8. PRE-CLEARANCE OF TRADES

- 8.1 Every Designated Person shall obtain a pre-clearance approval as per the procedure prescribed hereunder. For any dealing in any Securities of the Company proposed to be undertaken by such Designated Person/his /her Dependent such pre-clearance approval would be necessary, only if the market value of the securities of Entero Healthcare Solutions Limited involved in the aggregate in all dealings in a calendar month exceeds in a monetary terms, the amount of Rs. 5,00,000/- (Rupees Five Lakh).
- 8.2 However, no designated person shall be entitled to apply for preclearance of any proposed trade if such designated person is in possession of unpublished price sensitive information even if the trading window is not closed and hence he shall not be allowed to trade.
- 8.3 The pre-dealing procedure shall be hereunder:
 - a) For the purpose of obtaining a pre-clearance approval, the concerned Designated Person shall make an application in the prescribed form to the Compliance Officer (Refer Annexure A)
 - b) Such application should be complete and correct in all respects and should be accompanied by such undertakings, declarations, indemnity bonds and other documents/papers as may be prescribed by the Compliance Officer from time to-time (Refer Annexure B)
 - c) All Designated Person I his /her Dependent shall execute their order in respect of securities of the Company within one week after the approval of preclearance is given. The Designated Person I his /her Dependent shall file within 2 (two) trading days of the execution of the deal, the details of such deal with the Compliance Officer in the prescribed form. (Refer Annexure E) In case the transaction is not undertaken, a report to that effect shall be filed.
 - d) If the order is not executed within seven trading days after the approval is given, the employee/director must pre-clear the transaction again.
- 8.4 Designated person who is permitted to trade shall not execute a contra trade for six months from the date of entering into transaction. The Compliance Officer may be empowered to grant relaxation from strict application of such restriction for reasons to be recorded in writing

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com



provided that such relaxation does not violate these regulations.

8.5 Where any contra trade is executed, inadvertently or otherwise, in violation of such a restriction, the profits from such trade shall be liable to be surrendered for remittance to the Board for credit to the Investor Protection and Education Fund administered by the Board under the Act.

9. REPORTING AND DISCLOSURE REQUIREMENTS

- 9.1 All Directors/officers /designated employees shall be required to forward the following details of their securities transactions including the statement of dependent family members to the Compliance officer:
 - a) All holdings in securities of that Company by directors/ officers/ designated employees at the time of joining the company; (Refer Annexure D- Form A)
 - b) Trading in derivatives of securities and the traded value of the derivatives, if any
 - c) Periodic statement of any transactions in securities and The Compliance Officer shall maintain records of all the declarations in the appropriate form given by the directors/ officers I designated employees for a minimum period of five years.
- 9.2 The disclosures to be made hereunder shall include those relating to trading by such person's immediate relatives. and by any other person for whom such person takes trading decisions.
- 9.3 Initial Disclosure

Every Key Managerial Personnel or a Director and Promoter of the company on his appointment shall disclose in prescribed format (Refer Annexure E- Form B) his holding of securities of the company as on the date of appointment or becoming a promoter, to the company within 7 (seven) days of such appointment or becoming a promoter.

9.4 Continual Disclosure

Every Promoter, Employee and Director of the Company shall disclose to the company the number of such securities acquired or disposed of within 2 (two) trading days of such transaction if the value of the securities traded, whether in one transaction or a series of transactions

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com



over any calendar quarter, aggregates to a traded value in excess of Rs.5,00,000/- (Rupees Five Lakh) in Annexure F – Form C.

9.5 Disclosure by Company to the Stock Exchanges:

Notify the particulars of such trading to the stock exchange on which the securities are listed within 2 (two) trading days of receipt of the disclosure or from becoming aware of such information.

The Compliance Officer shall maintain records of all the above disclosures in an appropriate form for a minimum period of 5 (five) years from the date of the filing thereof.

10. REPORTING AND DISCLOSURE REQUIREMENTS

The following guidelines shall be followed with special reference to analysts, media persons and institutional investors:

a. Only public information to be provided.

b. At least two Company representatives be present at meetings with analysts, media persons and institutional investors.

c. Unanticipated questions may be taken on notice and a considered response given later. If the answer includes price sensitive information, a public announcement should be made before responding.

d. Simultaneous release of information after every such meet.

11. MAINTENANCE OF STRUCTURED DIGITAL DATABASE

- 11.1 The Company will maintain a structured digital database containing the names of such persons or entities as the case may be with whom information is shared under this Code of Conduct read with the Regulations, along with the Permanent Account Number or any other identifier authorized by law where Permanent Account Number is not available.
- 11.2 The said digital database shall be maintained with adequate internal controls and checks such as time stamping and audit trails to ensure non-tampering of the database.



12. MECHANISM FOR PREVENTION OF INSIDER TRADING

- 12.1 The Company has adopted system of internal controls which mainly consist of the following, to prevent dealing in securities by insiders with misuse of UPSI.
- 12.2 All employees who have access to UPSI are identified as designated employee
- 12.3 All UPSI shall be identified and its confidentiality shall be maintained by designated employee and others who have knowledge of unpublished price sensitive information.
- 12.4 Adequate restriction shall be placed on procurement, communication and sharing of UPSI by designated employee and others who have knowledge of UPSI.
- 12.5 List of employees and other persons with whom UPSI is shared shall be maintained and confidentiality agreement shall be executed or notice shall be served to all such employees and persons
- 12.6 Audit Committee shall review once in a financial year, the process to evaluate effectiveness of the above said internal controls and shall verify that the system for internal control are adequate and are operating effectively.
- 12.7 Audit committee shall review at least once in a financial year, compliance with this Code of Conduct read with the Regulations.

13. PENALTY

- 13.1 Every Designated Person shall be individually responsible for complying with the provisions of this Code of Conduct (including to the extent the provisions hereof are applicable to his/ her immediate Relatives).
- 13.2 The Designated Person who contravenes the Code of Conduct shall be penalised and shall also be subject to disciplinary action by the Company, which may include wage freeze, suspension etc.
- 13.3 The Company shall promptly inform the SEBI regarding any violation of the Code of Conduct.

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com

Corporate office : Unit No. 605 & 606, 6th Floor, Trade Centre, Bandra Kurla Complex, Bandra (East), Mumbai – 400051. Tel.: 022-26529100 / 69019100, CIN: U74999HR2018PLC072204



- 13.4 The action by the Company shall not preclude the SEBI from taking any action in case of violation of SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended.
- 13.5 Further Non -Adherence to any of the Clause as mentioned in this Policy will attract penalty of twenty-five thousand rupees and which may extend to five lakh rupees as prescribed under Section 188 of the Companies Act, 2013, and a penalty of one lakh rupees which may extend to one crore rupees as prescribed under Section 15 HB of SEBI Act, 1992.

14. CODE OF FAIR DISCLOSURE

- 14.1 Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information
- 14.2 Under Regulation 8(1) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. The principles for fair disclosure, in terms of the Code adopted by the Company are as follows:
 - a. The Company shall promptly make public disclosure of unpublished price sensitive information that would impact price discovery, as soon as it has credible and concrete information, in order to make such information generally available. Such disclosures shall be subject to internal corporate approvals and made through the authorized personnel of the Company. If any such information is accidentally disclosed without such approval, the person making such disclosure shall immediately inform the designated officer.
 - b. The Company shall make uniform and universal dissemination of unpublished price sensitive information to avoid selective disclosure.
 - c. The Company Secretary or such other person, as may he appointed by the Board shall serve as Chief Investor Relations Officer and is authorised for the purposes of this Code to deal with dissemination of information and disclosureof unpublished price sensitive information.
 - d. The Company shall make prompt dissemination of unpublished price sensitive information that gets disclosed selectively, inadvertently or otherwise if at all, to make such information generally available.

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com

Corporate office : Unit No. 605 & 606, 6th Floor, Trade Centre, Bandra Kurla Complex, Bandra (East), Mumbai – 400051. Tel.: 022-26529100 / 69019100, CIN: U74999HR2018PLC072204



- e. The Company shall make appropriate and fair response to queries on news reports and requests for verification of market rumour(s) by regulatory authorities.
- f. The Company shall ensure that information shared with analysts and research personnel is not unpublished price sensitive information. The Company shall endeavour that, where any unpublished price sensitive information is to be disclosed, before discussing or disclosing any such information to analysts or at any meeting, first the information be provided to the stock exchanges and where applicable, appropriate press releases be made, before any such meetings.
- g. The Company shall develop best practices to make available transcripts or records of proceedings of meetings with analysts and other investor relations conferences, on the website of the Company to ensure official confirmation and documentation of disclosures made.
- h. The Company shall handle all unpublished price sensitive information on a need-to know basis.
- i. Any subsequent modification(s) and amendment(s) to Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, to that extent, shall automatically apply to this Code.

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com



"Annexure 1"

This Annexure forms the part of this Code of Fair Disclosure of UPSI

POLICY FOR PROCEDURE OF INQUIRY IN CASE OF LEAK OF UNPUBLISHED PRICE SENSITIVE INFORMATION ("USPI")

[Under Regulation 9A of SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018]

1. BACKGROUND

The SEBI (Prohibition ofInsider Trading) (Amendment) Regulations, 2018 has mandated every listed company to formulate a written policy and procedures for inquiry in case of leak of unpublished price sensitive information and initiate appropriate inquiries on becoming aware of leak of unpublished price sensitive information and inform the Board promptly of such leaks, inquiries and results of such inquiries.

2. OBJECTIVES

- 2.1 To strengthen the internal control system to prevent leak of UPSI.
- 2.2 To restrict and prohibit the practice of sharing of UPSI, with the un-authorized person, which originates from within the Company and which affects the market price of the Company's securities as well as loss of reputation and investors' / financers' confidence in the Company.
- 2.3 To have a uniform code to curb the un-ethical practices of sharing UPSI by Insiders, Employee(s) & Designated Persons with any person, firm, company or Body Corporate.
- 2.4 To initiate inquiry in case of leak of UPSI or suspected leak of UPSI and inform the same to the SEBI promptly.
- 2.4 To penalize any Insider, Employee & Designated Persons who appears to have found guilty of violating this policy

3. DEFINATIONS

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com



- 3.1 Chief Investor Relation Officer (CIO) shall mean the Compliance Officer of the Company appointed by the Board of Director under Securities and Exchange Board India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3.2 Leak of UPSI shall mean communication of information which is I shall be UPSI by any Insider, Employee and Designated Persons or any other known or unknown person to any person other than a person(s) authorized by the Board of Directors of the Company after following the due process prescribed in this behalf in the Code of Practices Fair Disclosure of the Company and /or under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and/or SEBI (Prohibition of Insider Trading) Regulations, 2015 and any amendment, reamendment or re-enactment thereto.
- 3.3 Support Staff shall include IT staff or Secretarial Staff who have access to unpublished price sensitive information.
- 3.4 Unpublished Price Sensitive Information (UPSI) shall mean any information, relating to a Company or its securities, directly or indirectly, that is not generally available which upon becoming generally available, is likely to materially affect the price of the securities and shall, ordinarily include but not restricted to, information relating to the following:
 - a. Periodical financial results of the Company;
 - b. Intended declaration of dividends (Interim and Final);
 - c. Change in capital structure i.e. Issue of securities, buy back of securities or any forfeiture of shares or change in market lot of the Company's shares;
 - d. Mergers, De-mergers, Amalgamation, Acquisitions, De-listing of Securities, Scheme of Arrangement or Takeover, disposals, spin off or selling division of whole or substantially whole of the undertaking and expansion of business and such other transactions;
 - e. Any major expansion plans or execution of new projects or any significant changes in policies, plans or operations of the Company;
 - f. Changes in Key Managerial Personnel;

4. DUTIES OF CIO

The CIO shall be responsible to;

4.1 Oversee the Compliance of this policy.

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com



- 4.2 Report the incident of actual or suspected leak of UPSI to the SEBI.
- 4.3 Intimate the incident of actual or suspected leak of UPSI to the Stock Exchanges.
- 4.4 To co-ordinate with and disclose the relevant facts of the incident of actual or suspected leak of UPSI to the Enquiry Committee.

5. DISCLOSURE OF ACTUAL OR SUSPECTED LEAK OF UPSI TO STOCK EXCHANGES

5.1 On becoming aware of actual or suspected leak of UPSI of the Company, the CIO shall ensure that the same shall be promptly intimated to the Stock Exchanges on which the securities of the Company are listed in the format as set out in "Annexure-G" to this policy.

REPORT OF ACTUAL OF SUSPECTED LEAK OF UPSI TO SEBI

5.2 On becoming aware of actual or suspected leak of UPSI of the Company, the CIO shall ensure that a report on such actual or suspect leak of UPSI, preliminary enquiry thereon and results thereof shall be promptly made to the SEBI in the format as set out in "Annexure-H" to this policy.

6. CONSTITUTION OF ENQUIRY COMMITTEE

6.1 The Board of Directors or any Committee authorized by them in this behalf, shall constitute a committee to be called as "Enquiry Committee". The Enquiry Committee shall consist of minimum 3 (three) Members which shall include Managing Director, Chief Financial Officer and Chief Investor Relation Officer and any other officer of the Company as may be mutually decided by the members of the Committee.

7. DUTIES OF ENQUIRY COMMITTEE

The Enquiry Committee shall be responsible-:

- 7.1 To conduct a preliminary enquiry to ascertain the truth contained in the information or complaint pertaining to actual or suspected leak of UPSI, if any; and
- 7.2 To authorize any person to collect necessary support material; and to decide disciplinary action thereon.

8. PROCEDURE FOR ENQUIRY IN CASE OF LEAK OF UPSI

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com



- 8.1 On becoming aware of suo-moto or otherwise, of actual or suspected leak of UPSI of the Company by any Promoter including member of the promoter group, Director, Key Managerial Person, Insider, Employee, Designated person, Support Staff or any other known or unknown person, the CIO after informing the same to the Managing Director or Chief Financial Officer of the Company, shall follow the below mentioned procedure in order to enquire and/or investigate the matter to ensure-:
- I. Preliminary Enquiry:
- I.a. Preliminary enquiry is a fact-finding exercise. The object of preliminary enquiry is to ascertain the truth or otherwise of the allegations contained in the information or complaint, if any, and to collect necessary available material in support of the allegations, and thereafter to decide whether there is justification to embark on any disciplinary action.
- I.b. The Enquiry Committee shall appoint and/or authorize any person(s), as it may deem fit, to initiate/conduct an enquiry to collect the relevant fact, material substances on actual or suspected leak of UPSI.
- II. Report of Preliminary Enquiry to the Enquiry Committee:

The Person(s) appointed/authorized to enquire the matter of actual or suspected leak of UPSI submit his/her report to the Enquiry Committee within 7 (seven) days from the date of his appointment on this behalf.

III. Disciplinary Action:

The Disciplinary action(s) shall include, wage freeze, suspension, recovery, termination of employment contract/agreement etc., as may be decided by the Members of the Committee.

9. PENALTY

9.1 Further Non -Adherence to any of the Clause as mentioned in this Policy will attract penalty of twenty-five thousand rupees and which may extend to five lakh rupees as prescribed under Section 188 of the Companies Act, 2013, and a penalty which may extend to one crore rupees as prescribed under Section 15 HB of SEBI Act, 1992.

10. AMENDMENT

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com



- 10.1 The Board of Directors of the Company, subject to applicable laws, rules & regulations, may amend/ substitute any provision(s) with a new provision(s) or replace this entire Policy with a new Policy.
- 10.2 In any circumstance where the terms of this Policy differ from any law, rule, regulation etc. for the time being in force, the law, rule, regulation etc. shall take precedence over this Policy.
- 10.3 This Policy and any subsequent amendment(s) thereto, shall be promptly intimated to the Stock Exchanges, if required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and/or SEBI (Prohibition of Insider Trading) Regulations, 2015 and any amendment, re-amendment or re- enactment thereto.



Annexure "A"

APPLICATION FOR SEEKING PRE-CLEARANCE

Date:

To, The Compliance Officer Entero Healthcare Solutions Limited Plot No. I-35, Building -B, Industrial Area Phase-I,13/7 Mathura Road, Faridabad, Haryana-121003

Dear Sir/ Madam,

Sub: Application for seeking Pre-Clearance in securities of the Company

Pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended and the Company's Code of Conduct, I seek your approval for purchase/ sale/subscription of the securities of the Company as per the details provided below.

The said securities will be bought/ sole in the name of (myself/ my immediate relative) ______ whose Depository Participant and /or existing folio nos. are as under:

Seller'/	Type of	Name of	DP &	No. of	Amount
Buyer's	securities	company	Client ID <i>I</i>	securities	
Name			Folio No.		

I hereby declare that I am seeking this clearance on the basis that I do not have any Unpublished Price Sensitive Information as defined under the Regulations.

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com



Please find enclosed herewith an Undertaking as per format prescribed by you.

Thanking you

Yours faithfully,

(_____)

Designation: _____, PAN No.: _____

Department:

Place:



Annexure "B"

Date:

To, The Compliance Officer Entero Healthcare Solutions Limited Plot No. I-35, Building -B, Industrial Area Phase-I,13/7 Mathura Road, Faridabad, Haryana-121003 Dear Sir/ Madam,

Sub: Undertaking accompanying with Annexure "A"

I, (Name), (Designation) of the Company residing at ______., am desirous of dealing in _______securities of the Company as mentioned in my pre - clearance application dated ______. I hereby undertake the following that:

- (a) The securities in respect of which the approval is sought, will be held/have been held by the above named for a minimum period of six months (except for sale of shares acquired pursuant to ESOP Scheme).
- (b) I am not and do not expect to be in possession of any Unpublished Price Sensitive Information relating to the Securities at the time of the trading.
- (c) In case, I receive any Unpublished Price Sensitive Information after signing this Undertaking but before the execution of the deal, I shall inform the Compliance Officer of the change in the position and refrain from dealing in the securities till such information is made public.
- (d) I have not contravened the Company's Code of Conduct or the SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended.
- (e) I have made a full and true disclosure in the matter.

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com

Corporate office : Unit No. 605 & 606, 6th Floor, Trade Centre, Bandra Kurla Complex, Bandra (East), Mumbai – 400051. Tel.: 022-26529100 / 69019100, CIN: U74999HR2018PLC072204



(f) If approval is granted, I shall execute the deal within 7 (seven) trading days of the receipt of approval or such shorter period permitted in the approval, failing which I shall again seek pre-clearance.

Yours faithfully,

(_____)

Name:	, Employee No.:	CIN/DIN
1 (unifie)	<i>j</i> <u>Linipio</u> <i>j</i> ee 1 (o	

Designation: _____, PAN No.: _____

Department:

Place:



Annexure "C"

APPROVAL/ REJECTION OF PRE- CLEARANCE

Date:

Name:

Designation:_____Dear

Sir/ Madam,

Sub: Approval/ Rejection of Pre- Clearance

With reference to your Application cum Undertaking for Pre-clearance dated ______, we would like to inform you that your application to purchase / sell ______securities of the Company is hereby approved / rejected, subject to the following provisions which you need to observe in terms of the Company's Code of Conduct or the SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended while dealing in the securities:

- i) the transactions would have to be executed within 7 (seven) trading days and if the same is not executed within 7 (seven) trading days after the approval is given you would have to Pre- Clear the transactions once again;
- ii) you are not and do not expect to be in possession of any Unpublished Price Sensitive Information relating to the securities at the time of the Trading; iii) you have not contravened the Company's Code of Conduct or the SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended.
- iii) any transactions with regard to the securities under this approval should be communicated to the Company within 2 (two) trading days of the conclusion of the transactions as pre enclosed Reporting of Trade/Transaction Form as per Annexure "D"; and
- iv) you have made full and true disclosure in the matter.

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com

Corporate office : Unit No. 605 & 606, 6th Floor, Trade Centre, Bandra Kurla Complex, Bandra (East), Mumbai – 400051. Tel.: 022-26529100 / 69019100, CIN: U74999HR2018PLC072204



<u>Note 1</u>: According to the Regulations, "All director's officers/designated persons who buy or sell any number of shares of the Company cannot enter into an opposite transaction i.e. sell or buy any number of shares during the next six months following the prior transaction."

Exception:

An employee can exercise his ESOPs even ifhe has transacted in shares of the Company during the previous six months. However, once the shares acquired under the

ESOP Scheme are sold in the market, the restriction on buying would become applicable for next six months.

Thus, after the current sell transaction, you may continue to sell shares in the market, but will not be allowed to buy for the next six months from the date of your latest sale & vice Versa.

<u>Note 2</u>: In case you have received any "Unpublished Price Sensitive Information" after submission of your application for sale of shares, please inform the Compliance Officer of the change in the position and refrain from trading in the Securities till such information is made public.

Thanking you,

Yours faithfully,

For Entero Healthcare Solutions Limited,

Compliance Officer



Annexure "D"

WAIVER OF MINIMUM HOLDING PERIOD

Date:

The Compliance Officer Entero Healthcare Solutions Limited Plot No. I-35, Building -B, Industrial Area Phase-I,13/7 Mathura Road, Faridabad, Haryana-121003

Dear Sir/ Madam,

Sub: Waiver of Minimum Holding Period

I request you to grant me waiver of the minimum holding period of 6 (six) months as required under the Company's Code of Conduct with respect to ______ securities of the Company held by me/ my Dependent/ Persons deemed to be connected ______(Name) singly/ jointly acquired by me/ my Dependent / Persons deemed to be connected on _____(Date).

I desire to deal in the securities of the Company on account of following (give reasons and supporting documents).

I declare that:

- i) above details are true, correct and complete in all respect; and
- ii) I am not and do not expect to be in possession of any unpublished price sensitive information relating to the securities of the Company at the time of the trading.
- iii) The trade if made shall not be in contravention of the Code or the SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended.

Thanking you,

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com



Yours faithfully,

(_____)

Name: _____, Employee No.: _____ CIN/DIN_____

Designation: _____, PAN No.: _____

Department:

Place:



Annexure "E"

REPORTING OF TRADE / TRANSACTION

Date:

The Compliance Officer

Entero Healthcare Solutions Limited

Plot No. I-35, Building -B, Industrial

Area Phase-I,13/7 Mathura Road,

Faridabad, Haryana-121003

Dear Sir/ Madam,

Sub: Reporting of Trade/ Transaction

I hereby give intimation pursuant to the Company's Code of Conduct and according to approval of pre-clearance dated ______, I have executed a trade/ transaction on _____(date).

The detail of said trade / transaction is as under:

Type of securities	No. of Securities purchased /Sold	Name of Company	Name in which Bought/Sold	Average Gross Price per Securities Contracted	DP & Client ID/ Folio No.

Further I enclose herewith copy of Contract Note for your ready reference.

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com

Corporate office : Unit No. 605 & 606, 6th Floor, Trade Centre, Bandra Kurla Complex, Bandra (East), Mumbai – 400051. Tel.: 022-26529100 / 69019100, CIN: U74999HR2018PLC072204



I declare that the above information is correct and that no provision of the Code of Conduct and the Regulations have been violated while executing aforesaid trade / transaction.

I also declare that I have complied with the requirements of minimum period of 6 (six) months for entering into an opposite transaction in respect of said securities.

Or
According to approval of pre-clearance dated, I have not executed a trade / transaction due to(reason of non-trading).
I will take fresh pre-clearance for trades as and when I propose to trade in securities of the Company.
Yours faithfully,
()
Name:, Employee No.: CIN/DIN
Designation:, PAN No.:

Department:

Place:



Annexure-F

FORM C

Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 [Regulation 7 (2) read with Regulation 6(2)]

Name of the company: _____

ISIN of the company: _____

Details of change in holding of Securities of Promoter, Employee or Director of a listed company and other such persons as mentioned in Regulation 6(2).

Name,	Cate	Securiti	es	Securi	ties	%of					Mode of	Tra	ding i	n		Exchang
PAN	gory	held pr	ion	acquir	ed/	shar	reho	allo	tmen	of	acquisiti	der	ivative	es (Sj	pecify	e
No.,	of	neiu pr	101	Dispo	sed	ldin		t		intim	on	typ	e of co	ntra	ct,	on
CIN/DI	Pers	to		_			0	adv	ice/	ation	(market	Fut	ures o	r Op	tions	which
N,	on	acquisit	ion					acqu	uisiti		purchas	etc))	-		the trade
&	(Pro	acquisii	.1011					on c	of	comp any	e/					was
address	mot	/dispos	sal					shar	res/	arry	public					executed
of	e							sale	of		rights/					
Promoter	rs/							shar	res		preferen					
/	KM							spee	cify		tial					
Employe	Р/	Type of	No.	Type	No.	Pre	Pos	Fro	То		offer/	Buy	7	Sell		
e I	Dire	securit		of		tra	t	m			off					
Director	ctor	securit		secur		nsa	tra				market					
with	s/	y (For		ity		ctio	nsa				/ Inter-					
contact	imm edia	eg -		(For		n	ctio				se					
nos	te ₁	cg.		eg			n				transfer					
100	te relat iyes			Share							etc.					
	/			s,												
	othe			Warr												
	rs															
	etc.)			ants,												
		Shares,		Conv												
		Warran		ertib								Val	Num	Val	Num	
		ts,		le Debe								ue	ber		ber	
		Conver		nture									of		of	
		tible		s etc.)									units		units	
		Debent											(cont		(contr	
		ures											racts		acts	
		etc.)											* lot		* lot	
													size)		size)	
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com



Note: "*Securities*" *shall have the meaning as defined under regulation 2(1)(i) of SEBI (Prohibition of Insider Trading) Regulations, 2015.*

Signature:

Designation:

Date:



Annexure-G

INTIMATION OF ACTUAL OR SUSPECTED LEAK OF UPSI TO THE STOCK EXCHANGES

To BSE Limited P. J. Towers, Dalal Street, Fort, Mumbai - 400 001 Ref.: BSE Scrip Code No. 530431 Dear Sir/ Madam,

Sub: Intimation of actual or suspected leak of UPSI pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended, we are reporting actual or suspected leak of Unpublished Price Sensitive Information (UPSI) of the Company, as follows:

Name of Offender, if known	
Name of Organization	
Designation	
(Employee, Insider, Designated Person or any other)	
Nature of Information	
Whether any action initiated by the Company?	YES/NO
If yes, narration of the same	

Request you to kindly take the aforementioned on your records.

Thanking you,

Yours faithfully

For Entero Healthcare Solutions Limited

Compliance Officer

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com



Annexure-H

FORMAT FOR REPORTING ACTUAL OR SUSPECTED LEAK OF UPSI TO THE SEBI

To,

Securities and Exchange Board of India Plot No. C 4-A, G Block, Near Bank of India, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051

Ref.: BSE Scrip Code No. 530431

Dear Sir/ Madam,

Sub: Report of actual or suspected leak of UPSI pursuant to regulation 9A (5) of SEBI (Prohibition of Insider Trading) Regulation, 2015

Ref.: Security Code No. _____

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with Regulation 9A (5) of SEBI (Prohibition of Insider Trading) Regulation, 2015 as amended, we are reporting actual or suspected leak of Unpublished Price Sensitive Information (UPSI) of the Company, as follows:

Name of Offender, if known	
Name of Organization	
Designation	
(Employee, Insider, Designated Person or any other)	
Nature of Information	
Whether any action initiated by the Company?	YES/NO
If yes, narration of the same	

Request you to kindly take the aforementioned on your records.

Thanking you,

Yours faithfully For **Entero Healthcare Solutions Limited**

Compliance Officer

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com



"Annexure 2"

Policy for determination of "Legitimate Purpose" for sharing Unpublished Price Sensitive Information

[Pursuant to Securities and Exchange Board of India (Prohibition of Insider Trading) (Amendment) Regulations, 2018]

1. PREAMBLE AND OBJECTIVE

- 1.1. This "Policy for Determination of Legitimate Purpose" (this "Policy") is prepared in compliance with the provisions of Regulation 3(2A) read with Regulation 8(1) of Chapter IV of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (including any statutory amendment(s), modification(s) or re-enactment(s) thereof, for the time being in force) (the "SEBI {PIT) Regulations") and adopted by the Board of Directors (the "Board of Directors") of Entero Healthcare Solutions Limited (the "Company") on August 25, 2023 in order to establish a mechanism for sharing of Unpublished Price Sensitive Information (as defined hereinafter) in the ordinary course of business by an Insider (as defined hereinafter) of the Company.
- 1.2. The Company, in the course of its business, shares data or information with various persons such as organizations, agencies, institutions, intermediaries, establishments and other persons. Some of such unpublished data or information, if made publicly available could have the potential to materially impact the market price of the securities of the Company. If such a person trades on the basis of UPSI (as defined hereinafter), it could result in an undue advantage through an information asymmetry in the market.

Therefore, the trading in the securities of the Company by an Insider (as defined hereinafter) is governed by and is subject to the SEBI (PIT) Regulations.

1.3. Objective

The objective of this Policy is to lay down a broad policy for the determination of "Legitimate Purpose" as a part of the Code of Fair Disclosure of Unpublished Price Sensitive Information (the "Code"), pursuant to which UPSI may be shared.

2. PREAMBLE AND OBJECTIVE

Words and expressions used but not defined in this Policy shall have the same meaning assigned to them in the SEBI (PIT) Regulations or the Securities Contracts (Regulation) Act, 1956 or the Companies Act, 2013 and the rules and regulations made thereunder, as the case may be, including all amendments(s)/ modification(s) thereto.

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com



- 2.1. "Connected Person" shall mean Connected Person as defined under the SEBI (PIT) Regulations and shall also include promoters and their directors and key managerial personnel. (Regulation 2(1)(d))
- 2.2. An "Insider" shall mean any person who is a Connected Person or in possession of or having access to unpublished price sensitive information. (Regulation 2(1)(g))
- 2.3. The term "securities" shall have the same meaning as assigned to it under the Securities Contracts (Regulation) Act, 1956 (42 of 1956) and any modifications thereof.
- 2.4. The term "Unpublished Price Sensitive Information" or "UPSI" shall mean any information relating to the Company or its securities, directly or indirectly, that is not generally available, and which upon becoming generally available (accessible to the public on a non-discriminatory basis), is likely to materially affect the price of the securities and shall ordinarily include but not be limited to, information relating to financial results, dividends, change in capital structure, mergers, de-mergers, acquisitions, delisting, disposals and expansion of business and/or such other transactions and changes in key managerial personnel.

The Board of Directors/ Chief Executive Officer/ Chief Operating Officer/ Executive Director/ Chief Financial Officer from time to time may also determine such other information as they may deem fit as UPSI. (Regulation 2(1)(n))

2.5. The term "ordinary course of business" shall mean the usual transactions, customs and practices undertaken by the Company to conduct its lawful business operations and activities and includes all such activities which the Company can undertake as per its memorandum of association and articles of association.

3. SCOPE

- 3.1. This Policy shall form an integral part of the Code of Fair Disclosure of Unpublished Price Sensitive Information of the Company and shall be applicable to all Insiders. It shall be the responsibility of Insiders of the Company to ensure compliance with the SEBI (PIT) Regulations, guidelines, and other related statutes fully.
- 3.2. This Policy is effective from August 25, 2023

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com



4. LEGITIMATE PURPOSE

- 4.1. In line with sub-regulation 2A of Regulation 3 of SEBI (PIT) Regulations, **"Legitimate Purpose"** for sharing of UPSI by an Insider shall mean and include sharing of UPSI in a manner that meets the following criteria:
 - i. The sharing is strictly on a need-to-know basis;
 - ii. The sharing is in the interest of the Company;
 - iii. The sharing is with only one or more of the following persons, viz. Promoters, business associates, partners, collaborators, lenders, customers, suppliers, merchant bankers, legal advisors, auditors, insolvency professionals or other advisors or consultants; and
 - iv. The sharing has not been carried out to evade or circumvent the prohibitions laid down under the SEBI (PIT) Regulations.
- 4.2. The sharing of UPSI should not be with a mala fide intention, for personal gain, or an unauthorized disclosure, to evade or circumvent the provisions of the SEBI (PIT) Regulations etc.
- 4.3. When determining whether disclosure of UPSI is towards a Legitimate Purpose, the Insider shall assess whether the disclosure of such UPSI is mandatorily required to achieve the intended objective and is in the best interests of the Company.
- 4.4. No UPSI shall be disclosed in the event, the intended purpose or objective can be achieved without disclosure of UPSI, and such disclosure is otherwise not required to be disclosed in the ordinary course of business.
- 4.5. Any Insider proposing to disclose any UPSI which is not covered under this Policy and is not for Legitimate Purpose, then such disclosure shall necessarily require prior approval of the Board of Directors. The Insider shall disclose sufficient details including reasons for such disclosure and the nature of UPSI proposed to be disclosed and shall seek necessary approvals from the Board of Directors.
- 4.6. Any disclosure of UPSI towards discharge of legal obligations and performance of duties shall be deemed to be Legitimate Purpose and necessary confidentiality agreements and non-disclosure agreements shall need to be executed before sharing any UPSI in accordance with the Company's Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons. However, this shall not be applicable to requisition of information by a statutory authority in exercise of their powers under law.
- 4.7. In the following cases (which are illustrative in nature), sharing of UPSI shall be considered as legitimate purpose:

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com

Corporate office : Unit No. 605 & 606, 6th Floor, Trade Centre, Bandra Kurla Complex, Bandra (East), Mumbai – 400051. Tel.: 022-26529100 / 69019100, CIN: U74999HR2018PLC072204



i. For investigation, inquiry or request for information by statutory or governmental authorities or any other administrative body recognized by law.

Example: Any call for information or query received from the Ministry of Corporate Affairs, Income Tax Authority, Securities and Exchange Board of India ("SEBI"), Stock Exchanges, Reserve Bank of India, sectoral regulatory body, etc.

ii. Under any proceedings or pursuant to any order of courts or tribunals.

Example: National Company Law Tribunal, National Company Law Appellate Tribunal, Quasi-judicial authority, other Appellate Tribunals, Arbitration Proceedings, etc.

iii. As part of compliance with applicable laws, regulations, rules and requirements.

Example: Company Law, Securities Law, Income Tax Law, Banking Law, etc.

iv. Arising out of any contractual obligations or arrangement entered into by the Company set forth in any contract, agreement, arrangement, settlement, understanding or undertaking.

Example: Due diligence for any kind of restructuring, namely mergers & acquisitions, joint venture agreements, share purchase agreements, franchisee agreement, etc.

v. Arising out of business requirements including requirement for the purposes of promoting the business and strategies of business, which may require sharing of information with Promoters and Promoters in turn with their Promoters, as applicable, as well as by Promoters with their advisors, consultants, intermediaries, fiduciaries, etc on a need to know basis, in the interest of the Company.

Example: Some of the examples which are illustrative in nature are as mentioned below:

- Sharing the relevant UPS/ by Company or Promoter(s) for advice, consultation, valuation, fund raising or other intermediation and approvals in relation to the subject matter of a proposed deal/ assignment/ tie-up/ venture/ fund raising.
- Sharing the relevant UPS/ by Company or Promoter(s) with intermediaries, fiduciaries, merchant bankers, advisors, lawyers, bankers, consultants, valuers, auditors, insolvency professionals, business support agents, transaction processing service providers in order to avail professional services from them.
- Sharing the relevant UPS/ by Company or Promoter(s) for advice, consultation, transaction support, intermediation and approvals on projects relating to enterprise transformation, strategy, change management, analytics, re-organization, operation improvement, technology and similar domains.

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com



- Sharing the relevant UPS/ by Company or Promoter(s) with business partners to fulfil the terms and conditions of a business contract with a client, vendor, collaborator or lender.
- Sharing the relevant UPS/ by Company or Promoter(s) for advice, consultation, transaction support, intermediation and approvals in the process of evaluation of new products, business opportunities and new lines of business.
- Sharing the relevant UPS/ by Company or Promoter(s) with persons engaged or involved in the processes leading to disclosure of events set out in Schedule III to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- vi. Any other purpose as the Board of Directors may determine depending upon the transaction(s) or the facts of the case.

5. PURPOSE OF SHARING UPSI

- 5.1. Any person in receipt of UPSI pursuant to a Legitimate Purpose shall be considered an "Insider" for purposes of the SEBI (PIT) Regulations.
- 5.2. Such Insider is required to ensure the confidentiality of the UPSI shared, in compliance with the SEBI (PIT) Regulations.
- 5.3. Information may be shared with such Insider for a Legitimate Purpose with the understanding, on part of both the provider of UPSI and the recipient of UPSI, that such information is and shall be used only for a Legitimate Purpose.
- 5.4. Such person shall not trade in securities of the Company while in possession of UPSI.
- 5.5. The Insider shall conduct the following steps while sharing UPSI:
 - i. Satisfy that information is UPSI and that sharing of UPSI is for a Legitimate Purpose i.e. there is a co-relation or nexus between the UPSI proposed to be shared and the purported transaction and/or any other underlying reason. No UPSI shall be disclosed in the event the intended purpose or objective can be achieved without disclosure of UPSI, and such disclosure is otherwise not required to be disclosed in ordinary course;
 - ii. Identify the persons and organisations with whom such information is to be shared;
 - iii. Notify the recipient that the information that is being shared is UPSI and to maintain the confidentiality of such UPSI;
 - iv. Enter into a confidentiality or non-disclosure agreement with the recipient of UPSI;

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com

Corporate office : Unit No. 605 & 606, 6th Floor, Trade Centre, Bandra Kurla Complex, Bandra (East), Mumbai – 400051. Tel.: 022-26529100 / 69019100, CIN: U74999HR2018PLC072204



- v. Ensure that the mode of sharing UPSI shall be either by an email (addressed directly to the Insider) or via hard copy or by any other electronic mode or device, or provide access to the information, data, server with due acknowledgment thereof from the recipient;
- vi. Maintain the names of the persons (along with PAN or any other identifier where PAN is not available) with whom UPSI is shared. The database shall be maintained with adequate internal controls and checks such as time stamping and audit trails to ensure non-tampering of the database. This database shall be kept confidential.

6. NOTICE TO THE RECIPIENT OF UPSI

- 6.1. The recipient of UPSI, which is communicated for any "Legitimate Purpose", shall be considered as an "Insider" under the Code adopted by the Company and a notice shall be given to them in such respect (either by an email or via hard copy or any other electronic mode or device) by the person making the communication of UPSI:
 - i. To make the recipient aware that the information shared is or shall be UPSI and the entry shall be made in the Digital Database of the Company (as defined hereinafter);
 - ii. To make the recipient aware about the duties and responsibilities attached to the receipt of such UPSI and the liability attached to misuse or unwarranted use of the same;
 - iii. To instruct the recipient to not deal in the securities of the Company while in possession of UPSI;
 - iv. To instruct the recipient to maintain the confidentiality of such UPSI in compliance with the Code and the other applicable laws; and
 - v. To advise the recipient to be in compliance with applicable provisions of the SEBI (PIT) Regulations.

7. RESPONSIBILITY OF THE RECIPIENT OF UPSI

- 7.1. The recipient of UPSI shall undertake:
- i. To maintain confidentiality of the information received;
- ii. To use the confidential information only for legitimate purpose;

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com



- iii. To disclose confidential information to any other person strictly on a need-to-know basis and after consulting and taking approval of the Compliance Officer of the Company;
- iv. To safeguard the UPSI with the same degree of care as the receiving party uses to protect its own confidential information, but in no case less than reasonable care, to avoid unauthorized disclosure; and
- v. To comply with applicable provisions of the SEBI (PIT) Regulations.

8. STRUCTURED DIGITAL DATABASE

- 8.1. The Insider sharing UPSI for legitimate purpose is required to make an entry in the structured digital database of the Company ("Digital Database") w.r.t the nature of UPSI, the name and permanent account number (PAN} or such other identifier authorized by the law where permanent account number is not available, of such persons or entities with whom UPSI is shared OR Insider may inform (in writing) to the Compliance Officer to record the same in the Digital Database;
- 8.2. The Digital Database shall be maintained internally with adequate internal controls and checks such as time stamping and audit trails etc. to ensure non-tampering of the Digital Database;
- 8.3. The Compliance Officer shall ensure that the Digital Database is preserved for a period of not less than 8 years after completion of the relevant transactions and in the event of receipt of any information from the SEBI regarding any investigation or proceedings, the relevant information in the Digital Database shall be preserved till the completion of such proceedings.
- 8.4. The format of the Digital Database has not been prescribed as on the date of this Policy. Whenever the Securities Exchange Board of India (SEBI) prescribes the format, the same shall be adopted by the Company. Until then, the format laid down in Annexure A shall be used.

9. RESTRICTIONS ON COMMUNICATION & TRADING BY INSIDERS

9.1. The Board of Directors shall require the Insiders to execute agreements to contract confidentiality and non-disclosure obligations on the part of such Insiders and such Insiders shall keep information so received confidential and shall not trade in securities of the Company when in possession of UPSI.

Registered office : Plot No. I-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003. Tel.: 0129-4877300, Email Id : info@enterohealthcare.com, Website : www.enterohealthcare.com

Corporate office : Unit No. 605 & 606, 6th Floor, Trade Centre, Bandra Kurla Complex, Bandra (East), Mumbai – 400051. Tel.: 022-26529100 / 69019100, CIN: U74999HR2018PLC072204



10. DISSEMINATION OF INFORMATION

- 10.1. The Board of Directors of the Company has appointed a Compliance Officer who shall be reporting to the Chief Financial Officer of the Company to deal with the dissemination of information and disclosure of UPSI.
- 10.2. The responsibility for adherence to this Policy shall however vests entirely with the person who is sharing the UPSI as well as the recipient of the UPSI.

11. PENALTIES AND FINES

- 11.1. Any sharing of UPSI, other than in compliance with this Policy and the SEBI (PIT) Regulations, shall be construed as a violation. The onus lies on the Insider to prove to the contrary.
- 11.2. In case of any violation of this Policy, disciplinary action shall be taken by the Company. The Company shall also inform SEBI about the violation.

12. SYSTEM AUDIT

12.1. There shall be a yearly audit (once in a financial year) to ensure the integrity of the system and the data maintained. The auditor(s) for this purpose will be decided by the Company, to whom the auditor(s) will be submitting their final report for review and compliance, as required.

13. POLICY REVIEW

- 13.1. This Policy shall be reviewed once in a financial year in accordance with the review of internal control and checks as well as changes in any regulatory requirements from time to time.
- 13.2. In the events of inconsistency of this Policy with any legal provisions, the provisions of law shall override this Policy.